Context Therapeutics Inc (CNTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Context Therapeutics Inc (CNTX) has a cash flow conversion efficiency ratio of -0.219x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.43 Million) by net assets ($52.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CNTX net asset value for net asset value and shareholders' equity analysis.
Context Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Context Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Context Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Context Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thantawan Industry Public Company Limited
BK:THIP
|
-0.005x |
|
CTI Traffic Industries Co Ltd
TWO:2230
|
-0.134x |
|
Sukhjit Starch & Chemicals Limited
NSE:SUKHJITS
|
-0.146x |
|
Globaltec Formation Bhd
KLSE:5220
|
0.061x |
|
Hoang Quan Consulting Trading Service Real Estate Corp
VN:HQC
|
0.115x |
|
Pengana Capital Group Ltd
AU:PCG
|
-0.006x |
|
Mediaco Holding Inc
NASDAQ:MDIA
|
0.001x |
|
Duroc AB (publ)
ST:DURC-B
|
0.023x |
Annual Cash Flow Conversion Efficiency for Context Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Context Therapeutics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Context Therapeutics Inc (CNTX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $60.47 Million | $-26.39 Million | -0.436x | -185.56% |
| 2024-12-31 | $95.27 Million | $-14.56 Million | -0.153x | +91.38% |
| 2023-12-31 | $11.87 Million | $-21.05 Million | -1.773x | -354.84% |
| 2022-12-31 | $34.76 Million | $-13.55 Million | -0.390x | -113.84% |
| 2021-12-31 | $48.27 Million | $-8.80 Million | -0.182x | -398.13% |
| 2020-12-31 | $-16.92 Million | $-1.03 Million | 0.061x | -48.34% |
| 2019-12-31 | $-23.96 Million | $-2.84 Million | 0.118x | +131.22% |
| 2017-12-31 | $58.95 Million | $-22.35 Million | -0.379x | +83.73% |
| 2016-12-31 | $13.12 Million | $-30.57 Million | -2.331x | -- |
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the de… Read more